PetCure Oncology
PetCure Oncology operates a national network of veterinary cancer care centers delivering stereotactic radiation therapy (SRS/SRT) to dogs and cats through partnerships with specialty hospitals, serving pet parents referred by primary care veterinarians.
- Company typePrivate
- Founded2015
- HeadquartersDeerfield, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What PetCure Oncology does
PetCure Oncology operates a national network of veterinary cancer care centers that deliver advanced radiation therapy to dogs and cats, with headquarters in Bannockburn, Illinois, operating as a subsidiary of Thrive Pet Healthcare. Founded in 2015 and originating from founder Scott Milligan's personal experience with pet cancer, the company pioneered the adaptation of stereotactic radiosurgery and stereotactic radiation therapy (SRS/SRT) — a high-dose, sub-millimeter-precision radiation modality standard in human oncology — for veterinary use. Treatment is completed in 1–3 sessions compared to 15–21 sessions for conventional veterinary radiation therapy, with a dual board-certified radiation oncologist review protocol applied to every case.
The technology stack centers on Varian Halcyon linear accelerators with RapidArc volumetric modulated arc therapy and on-board imaging, Eclipse treatment planning software, and the Radialogica fullAccess clinical collaboration platform that enables remote plan review and quality benchmarking across the network. Supporting services include medical oncology (chemotherapy), telehealth consultations, clinical trials (such as the canine lung tumor SRS trial published in JAVMA), and a Pet Advocate Team that guides pet parents through the care pathway. The Sirius Advanced Radiation Platform, developed in partnership with Empyrean Medical Systems, is scheduled for first installation at PetCure Seattle in early 2026.
PetCure generates revenue primarily through per-case professional service fees for SRS/SRT treatment, with case pricing ranging from approximately $3,000 to $13,000, paid by pet owners via pet health insurance, CareCredit financing, or direct payment. The go-to-market operates through three channels: an enterprise field-sales motion that recruits partner specialty veterinary hospitals to host PetCure's technology and clinical staff; a direct-to-consumer motion via the website, phone (833-738-4376), and telehealth that targets pet parents; and a referral/affiliate channel that funnels patients from primary care veterinarians through a dedicated referral form and complimentary imaging reviews. As of January 2026, the network comprised 8 confirmed treatment centers across Chicago, Clifton NJ, Dallas-Fort Worth, Phoenix, Pittsburgh, San Antonio, and San Jose, with additional locations in development, and the company had treated more than 10,000 pet patients cumulatively.
PetCure Oncology firmographics
Firmographics- Name
- PetCure Oncology
- Legal name
- PetCure Oncology
- Website
- https://petcureoncology.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PetCure Oncology operates a national network of veterinary cancer care centers delivering stereotactic radiation therapy (SRS/SRT) to dogs and cats through partnerships with specialty hospitals, serving pet parents referred by primary care veterinarians.
- Ownership category
- akta.pro rank
PetCure Oncology industry classification
Industry- Product category
- Veterinary Oncology Services
- NAICS
- Veterinary Services (54194), Veterinary Services (541940)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Veterinary Internal Medicine & Oncology Centers (HLAMACAD)
- akta.pro secondary industries
- Veterinary Surgery Centers (Soft Tissue/Orthopedic/Neuro) (HLAMACAC), Medical Oncology (HLAKAFAB)
Keywords
Where PetCure Oncology is headquartered
LocationHeadquarters
- HQ city
- Deerfield
- HQ country
- United States
- HQ region
- North America
Offices8 records
Markets served
PetCure Oncology business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- SRS/SRT Radiation Therapy Treatment Fees: PetCure generates revenue by providing stereotactic radiation therapy services to pet owners at its network of cancer care centers. Treatment is billed per procedure or as a treatment package. Pet owners pay directly, typically using pet health insurance, CareCredit financing, or major credit cards. The company has stated a cost range of approximately $3,000 to $13,000 for radiation therapy, varying by case specifics.
- Clinical Trial Subsidized Treatment Revenue: PetCure enrolls pets in clinical trials (e.g., canine lung tumor SRS trial) offering heavily subsidized treatment costs in exchange for research participation. While costs are subsidized for participants, this program generates clinical data and drives future revenue by building evidence and reputation for SRS efficacy in veterinary medicine.
- Telehealth Consultations: PetCure offers telehealth (video conferencing) consultations for initial appointments, allowing pet owners to speak with a PetCure oncology specialist remotely before committing to treatment. Telehealth visits may be billed as professional service consultations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | SRS/SRT Radiation Therapy — price varies by case, approximately $3,000–$13,000 |
| Other | Pay-as-you-go | Clinical Trial Treatment — heavily subsidized or free for eligible participants |
| Other | Pay-as-you-go | Telehealth Initial Consultations — included in care pathway |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
PetCure Oncology product offering
Product offeringCore offering
PetCure Oncology delivers stereotactic radiation therapy (SRS/SRT) and medical oncology services to dogs and cats with cancer through a national network of partner-hospital cancer care centers staffed by board-certified veterinary radiation oncologists. Treatments are planned with Eclipse software, delivered using Varian linear accelerators with RapidArc technology, and quality-managed via the Radialogica fullAccess platform. Pet owners access care directly or through primary care veterinarian referrals, with telehealth available for initial consults and clinical trials offered for eligible patients.
Product overview
PetCure Oncology is a veterinary oncology provider operating a national network of cancer care centers offering advanced radiation therapy treatments for pets. The core offering is Stereotactic Radiation (SRS/SRT), an advanced form of radiation therapy adapted from human medicine that delivers precise, high-dose treatments in just 1-3 sessions. Services are delivered through partnerships with specialty veterinary hospitals across the country, providing treatment at multiple locations. Additional services include Medical Oncology, Telehealth consultations, and access to Clinical Trials. The company also recently announced a partnership to bring the Sirius(TM) Advanced Radiation Platform to its network. PetCure Oncology supports patients through a Pet Advocate Team and utilizes advanced technology including the Varian Halcyon Treatment System with RapidArc technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Stereotactic Radiation (SRS/SRT) Advanced form of radiation therapy that delivers high-dose, sub-millimeter-precise radiation treatments in 1–3 sessions, compared to 15–21 sessions with traditional radiation therapy. Non-surgical, designed to treat tumors in sensitive locations (brain, spine, nasal) with curative or palliative intent for dogs and cats.
- Medical Oncology
Quantifiable outcome
- SRS/SRT is completed in 1–3 sessions vs. 15–21 sessions for conventional fractionated radiation therapy, representing an 80–95% reduction in treatment sessions and anesthetic events.
- +5 more outcomes
Companies that use PetCure Oncology
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
PetCure Oncology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
PetCure Oncology partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Empyrean Medical Systems Inc.flagshipEmpyrean Medical Systems partnered with Thrive Pet Healthcare to introduce the Sirius Advanced Radiation Platform for veterinary cancer care. The first installation is planned for early 2026 at PetCure Oncology in Seattle, marking Empyrean's entry into the veterinary therapeutics market. The Sirius platform enables highly targeted, high-dose radiation therapy for pets with cancer, aiming to improve treatment safety and effectiveness.
- Varian Medical Systems (Halcyon Treatment System)corePetCure Oncology selected the Varian Halcyon treatment system to expand access to cancer care for pets. Varian provides linear accelerators featuring RapidArc volumetric modulated arc therapy technology and on-board imaging for image-guided radiation therapy. The Halcyon system was deployed at PetCure's partner locations (e.g., SAGE Centers in Campbell, CA). Varian is a leading manufacturer of radiation therapy equipment for human medicine.
- RadialogicacorePetCure Oncology selected Radialogica's fullAccess software platform for clinical collaboration and quality management across its network of cancer care centers. The platform provides vendor-independent radiotherapy data visualization, analytics to benchmark treatment plan quality and safety, and clinical collaboration tools enabling clinicians across locations to access, analyze, and share treatment plans remotely. This partnership applies best practices from human oncology quality management to veterinary radiation therapy.
Scale indicators4 records
Recent moves5 records
Expansion highlights6 records
PetCure Oncology competitors and assessment
Company assessmentBroad incumbents
- Thrive Pet Healthcare: Parent company of PetCure Oncology and operator of a growing national network of specialty, emergency, and primary care veterinary hospitals. Strategically adjacent as the platform through which PetCure scales its cancer care centers.
- Mars Veterinary Health (BluePearl/VCA/NVA): Parent of BluePearl, VCA, and NVA, making it the largest specialty veterinary hospital operator in North America. Relevant as a scaled incumbent that increasingly competes with PetCure for advanced veterinary oncology referrals.
- BluePearl Pet Hospital: Large network of specialty and emergency veterinary hospitals offering oncology, internal medicine, and surgery. Like PetCure, BluePearl is a multi-site specialty platform, but operates general specialty hospitals rather than a dedicated SRS network.
- VCA Animal Hospitals: Operates a national network of specialty and primary care veterinary hospitals, including oncology services. Broader in scope than PetCure and lacks a focused SRS/SRT specialty offering, but competes for the same specialty referral pool.
Others
- Varian Medical Systems (Siemens Healthineers): Manufacturer of the Halcyon and TrueBeam linear accelerators and Eclipse treatment planning software that PetCure deploys. Relevant as a key technology supplier and as the human oncology technology parent whose hardware PetCure adapts for veterinary use.
Direct peers
- Ethos Veterinary Health: Network of specialty and emergency veterinary hospitals that includes veterinary oncology and radiation therapy capabilities. Most direct comparable to PetCure as a multi-site veterinary specialty and oncology operator serving similar referring vets and pet parents.
- Compassion-First Pet Hospitals: Network of specialty and emergency veterinary hospitals, many with oncology services, serving referring primary care veterinarians in the U.S. Comparable to PetCure in its specialty-only model and referral-driven GTM.
- MedVet: Specialty and emergency veterinary hospital network with oncology, internal medicine, and surgery across multiple U.S. markets. Comparable to PetCure as a specialty-only multi-site competitor for oncology referrals and pet parent demand.
Emerging players
- Veterinary Cancer Group: California-based specialty veterinary oncology practice offering medical oncology and radiation therapy. Overlaps with PetCure in oncology services but is a regional/emerging player without PetCure's national network or SRS specialization.
- Empyrean Medical Systems: Developer of the Sirius™ Advanced Radiation Platform, which PetCure is bringing into veterinary use via its 2025 partnership with Thrive. Relevant as both an emerging technology partner and a future potential competitor if the Sirius platform expands beyond PetCure's network.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
PetCure Oncology social profiles
Digital presencePetCure Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
PetCure Oncology leadership team
Management profileNumber of profiles
Profiles3 records
PetCure Oncology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PetCure Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PetCure Oncology
What does PetCure Oncology do?
PetCure Oncology delivers stereotactic radiation therapy (SRS/SRT) and medical oncology services to dogs and cats with cancer through a national network of partner-hospital cancer care centers staffed by board-certified veterinary radiation oncologists. Treatments are planned with Eclipse software, delivered using Varian linear accelerators with RapidArc technology, and quality-managed via the Radialogica fullAccess platform. Pet owners access care directly or through primary care veterinarian referrals, with telehealth available for initial consults and clinical trials offered for eligible patients.
Is PetCure Oncology a public or private company?
PetCure Oncology is a private company. It is classified as corporate owned and is currently operating.
When was PetCure Oncology founded?
PetCure Oncology was founded in 2015. It employs 11 to 50 people.
Where is PetCure Oncology based?
PetCure Oncology is headquartered in Deerfield, United States, in the North America region.
How does PetCure Oncology make money?
Three revenue lines are on record. SRS/SRT Radiation Therapy Treatment Fees are the primary driver. The others are clinical Trial Subsidized Treatment Revenue and telehealth Consultations.
Who are PetCure Oncology's main competitors?
Broad incumbents on record are Thrive Pet Healthcare, Mars Veterinary Health (BluePearl/VCA/NVA), BluePearl Pet Hospital and VCA Animal Hospitals. Varian Medical Systems (Siemens Healthineers) is listed as an others. Direct peers are Ethos Veterinary Health, Compassion-First Pet Hospitals and MedVet. Emerging players are Veterinary Cancer Group and Empyrean Medical Systems.
Does PetCure Oncology have an API?
No public API is recorded for PetCure Oncology.
What industry is PetCure Oncology in?
PetCure Oncology's product category is Veterinary Oncology Services. Its primary akta.pro industry code is HLAMACAD, Veterinary Internal Medicine & Oncology Centers, with a secondary code of HLAMACAC, Veterinary Surgery Centers (Soft Tissue/Orthopedic/Neuro). Its NAICS code is 54194 and its SIC code is 8011.